转移性非小细胞肺癌：欧洲肿瘤内科学会临床实践诊断、治疗及随访指南 - Suppr

Suppr

超能文献

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

作者信息

D'Addario G, Früh M, Reck M, Baumann P, Klepetko W, Felip E

机构信息

Onkologie Schaffhausen, Switzerland.

出版信息

Ann Oncol. 2010 May;21 Suppl 5:v116-9. doi: 10.1093/annonc/mdq189.

DOI:10.1093/annonc/mdq189

PMID:20555059

Abstract

摘要

相似文献

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2010 May;21 Suppl 5:v116-9. doi: 10.1093/annonc/mdq189.

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2012 Oct;23 Suppl 7:vii56-64. doi: 10.1093/annonc/mds226.

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC).

Ann Oncol. 2005;16 Suppl 1:i28-9. doi: 10.1093/annonc/mdi821.

Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2010 May;21 Suppl 5:v103-15. doi: 10.1093/annonc/mdq207.

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2010 May;21 Suppl 5:v120-5. doi: 10.1093/annonc/mdq172.

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237. doi: 10.1093/annonc/mdy275.

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2014 Sep;25 Suppl 3:iii27-39. doi: 10.1093/annonc/mdu199. Epub 2014 Aug 11.

Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Ann Oncol. 2008 May;19 Suppl 2:ii39-40. doi: 10.1093/annonc/mdn081.

Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol. 2013 Oct;24 Suppl 6:vi89-98. doi: 10.1093/annonc/mdt241. Epub 2013 Jul 16.

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC).

Ann Oncol. 2001 Aug;12(8):1049-50. doi: 10.1023/a:1017480501194.

引用本文的文献

Mediastinal staging of nonsmall cell lung cancer: what's new?

Breathe (Sheff). 2025 Jul 15;21(3):230191. doi: 10.1183/20734735.0191-2023. eCollection 2025 Jul.

Drug-Eluting Beads Bronchial Arterial Chemoembolization Combined with Immunotherapy Resulted in Pathological Complete Response of Squamous Cell Lung Cancer: A Case Report.

Int Med Case Rep J. 2024 Dec 18;17:1041-1047. doi: 10.2147/IMCRJ.S491862. eCollection 2024.

Patients' psychosocial attributes and aggressiveness of cancer treatments near the end of life.

Oncologist. 2025 Feb 6;30(2). doi: 10.1093/oncolo/oyae317.

Uncommon Manifestations of Lung Cancer: Diagnostic Challenges and Valuable Insights From a Rare Clinical Case.

Cureus. 2024 Oct 11;16(10):e71249. doi: 10.7759/cureus.71249. eCollection 2024 Oct.

Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer.

PLoS One. 2024 May 16;19(5):e0303046. doi: 10.1371/journal.pone.0303046. eCollection 2024.

An epidermal growth factor receptor compound mutation of L858R with S768I in advanced non-small-cell lung cancer: a case report.

J Med Case Rep. 2024 Mar 18;18(1):118. doi: 10.1186/s13256-024-04422-5.

Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with/without upfront LT.

J Cancer Res Clin Oncol. 2024 Feb 19;150(2):94. doi: 10.1007/s00432-023-05538-9.

FOXA1 prolongs S phase and promotes cancer progression in non-small cell lung cancer through upregulation of CDC5L and activation of the ERK1/2 and JAK2 pathways.

Kaohsiung J Med Sci. 2023 Nov;39(11):1077-1086. doi: 10.1002/kjm2.12737. Epub 2023 Sep 2.

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.

ESMO Open. 2023 Aug;8(4):101580. doi: 10.1016/j.esmoop.2023.101580. Epub 2023 Jun 28.

Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands.

Sci Rep. 2023 Feb 9;13(1):2349. doi: 10.1038/s41598-023-29286-5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验